The Experts below are selected from a list of 75390 Experts worldwide ranked by ideXlab platform
Tuck Y. Yong - One of the best experts on this subject based on the ideXlab platform.
-
Non-contiguous multifocal vertebral Osteomyelitis caused by Serratia marcescens.
Modern rheumatology, 2014Co-Authors: Jen Xin Lau, Tuck Y. YongAbstract:Serratia marcescens is a common nosocomial infection but a rare cause of Osteomyelitis and more so of vertebral Osteomyelitis. Vertebral Osteomyelitis caused by this organism has been reported in few studies. We report a case of S. marcescens vertebral discitis and Osteomyelitis affecting multiple non-contiguous vertebras. Although Staphylococcus aureus is the most common cause of vertebral Osteomyelitis, rare causes, such as S. marcescens, need to be considered, especially when risk factors such as intravenous heroin use, post-spinal surgery and immunosuppression are present. Therefore, blood culture and where necessary biopsy of the infected region should be undertaken to establish the causative organism and determine appropriate antibiotic susceptibility. Prompt diagnosis of S. marcescens vertebral Osteomyelitis followed by the appropriate treatment can achieve successful outcomes.
Ernie L Esquivel - One of the best experts on this subject based on the ideXlab platform.
-
impact of diagnostic bone biopsies on the management of non vertebral Osteomyelitis a retrospective cohort study
Medicine, 2019Co-Authors: Cole B Hirschfeld, Shashi N Kapadia, Joanna Bryan, Deanna Jannatkhah, Benjamin May, Ole Vielemeyer, Ernie L EsquivelAbstract:AbstractOptimal antibiotic management of patients with Osteomyelitis remains a challenge for many clinicians. Although image-guided bone biopsy (IGB) remains the gold standard, its role in confirming diagnosis and guiding antibiotic management is not clear in patients with non-vertebral osteomyeliti
Jen Xin Lau - One of the best experts on this subject based on the ideXlab platform.
-
Non-contiguous multifocal vertebral Osteomyelitis caused by Serratia marcescens.
Modern rheumatology, 2014Co-Authors: Jen Xin Lau, Tuck Y. YongAbstract:Serratia marcescens is a common nosocomial infection but a rare cause of Osteomyelitis and more so of vertebral Osteomyelitis. Vertebral Osteomyelitis caused by this organism has been reported in few studies. We report a case of S. marcescens vertebral discitis and Osteomyelitis affecting multiple non-contiguous vertebras. Although Staphylococcus aureus is the most common cause of vertebral Osteomyelitis, rare causes, such as S. marcescens, need to be considered, especially when risk factors such as intravenous heroin use, post-spinal surgery and immunosuppression are present. Therefore, blood culture and where necessary biopsy of the infected region should be undertaken to establish the causative organism and determine appropriate antibiotic susceptibility. Prompt diagnosis of S. marcescens vertebral Osteomyelitis followed by the appropriate treatment can achieve successful outcomes.
J Ferguson - One of the best experts on this subject based on the ideXlab platform.
-
the use of a biodegradable antibiotic loaded calcium sulphate carrier containing tobramycin for the treatment of chronic Osteomyelitis a series of 195 cases
Journal of Bone and Joint Surgery-british Volume, 2014Co-Authors: J Ferguson, M Dudareva, Nicholas Riley, D Stubbs, Bridget L Atkins, M McnallyAbstract:We report our experience using a biodegradable calcium sulphate antibiotic carrier containing tobramycin in the surgical management of patients with chronic Osteomyelitis. The patients were reviewed to determine the rate of recurrent infection, the filling of bony defects, and any problems with wound healing. A total of 193 patients (195 cases) with a mean age of 46.1 years (16.1 to 82.0) underwent surgery. According to the Cierny–Mader classification of Osteomyelitis there were 12 type I, 1 type II, 144 type III and 38 type IV cases. The mean follow-up was 3.7 years (1.3 to 7.1) with recurrent infection occurring in 18 cases (9.2%) at a mean of 10.3 months post-operatively (1 to 25.0). After further treatment the infection resolved in 191 cases (97.9%). Prolonged wound ooze (longer than two weeks post-operatively) occurred in 30 cases (15.4%) in which there were no recurrent infection. Radiographic assessment at final follow-up showed no filling of the defect with bone in 67 (36.6%), partial filling in 108 (59.0%) and complete filling in eight (4.4%). A fracture occurred in nine (4.6%) of the treated osteomyelitic segments at a mean of 1.9 years (0.4 to 4.9) after operation. We conclude that Osteoset T is helpful in the management of patients with chronic Osteomyelitis, but the filling of the defect in bone is variable. Prolonged wound ooze is usually self-limiting and not associated with recurrent infection. Cite this article: Bone Joint J 2014; 96-B:829–36
-
the use of a biodegradable antibiotic loaded calcium sulphate carrier containing tobramycin for the treatment of chronic Osteomyelitis a series of 195 cases
Journal of Bone and Joint Surgery-british Volume, 2014Co-Authors: J Ferguson, M Dudareva, Nicholas Riley, D Stubbs, Bridget L Atkins, M A McnallyAbstract:We report our experience using a biodegradable calcium sulphate antibiotic carrier containing tobramycin in the surgical management of patients with chronic Osteomyelitis. The patients were reviewed to determine the rate of recurrent infection, the filling of bony defects, and any problems with wound healing. A total of 193 patients (195 cases) with a mean age of 46.1 years (16.1 to 82.0) underwent surgery. According to the Cierny-Mader classification of Osteomyelitis there were 12 type I, 1 type II, 144 type III and 38 type IV cases. The mean follow-up was 3.7 years (1.3 to 7.1) with recurrent infection occurring in 18 cases (9.2%) at a mean of 10.3 months post-operatively (1 to 25.0). After further treatment the infection resolved in 191 cases (97.9%). Prolonged wound ooze (longer than two weeks post-operatively) occurred in 30 cases (15.4%) in which there were no recurrent infection. Radiographic assessment at final follow-up showed no filling of the defect with bone in 67 (36.6%), partial filling in 108 (59.0%) and complete filling in eight (4.4%). A fracture occurred in nine (4.6%) of the treated osteomyelitic segments at a mean of 1.9 years (0.4 to 4.9) after operation. We conclude that Osteoset T is helpful in the management of patients with chronic Osteomyelitis, but the filling of the defect in bone is variable. Prolonged wound ooze is usually self-limiting and not associated with recurrent infection.
M A Mcnally - One of the best experts on this subject based on the ideXlab platform.
-
the use of a biodegradable antibiotic loaded calcium sulphate carrier containing tobramycin for the treatment of chronic Osteomyelitis a series of 195 cases
Journal of Bone and Joint Surgery-british Volume, 2014Co-Authors: J Ferguson, M Dudareva, Nicholas Riley, D Stubbs, Bridget L Atkins, M A McnallyAbstract:We report our experience using a biodegradable calcium sulphate antibiotic carrier containing tobramycin in the surgical management of patients with chronic Osteomyelitis. The patients were reviewed to determine the rate of recurrent infection, the filling of bony defects, and any problems with wound healing. A total of 193 patients (195 cases) with a mean age of 46.1 years (16.1 to 82.0) underwent surgery. According to the Cierny-Mader classification of Osteomyelitis there were 12 type I, 1 type II, 144 type III and 38 type IV cases. The mean follow-up was 3.7 years (1.3 to 7.1) with recurrent infection occurring in 18 cases (9.2%) at a mean of 10.3 months post-operatively (1 to 25.0). After further treatment the infection resolved in 191 cases (97.9%). Prolonged wound ooze (longer than two weeks post-operatively) occurred in 30 cases (15.4%) in which there were no recurrent infection. Radiographic assessment at final follow-up showed no filling of the defect with bone in 67 (36.6%), partial filling in 108 (59.0%) and complete filling in eight (4.4%). A fracture occurred in nine (4.6%) of the treated osteomyelitic segments at a mean of 1.9 years (0.4 to 4.9) after operation. We conclude that Osteoset T is helpful in the management of patients with chronic Osteomyelitis, but the filling of the defect in bone is variable. Prolonged wound ooze is usually self-limiting and not associated with recurrent infection.
